A built‐in electric field in electrocatalyst can significantly accumulate higher concentration of NO3− ions near electrocatalyst surface region, thus facilitating mass transfer for efficient nitrate ...removal at ultra‐low concentration and electroreduction reaction (NO3RR). A model electrocatalyst is created by stacking CuCl (111) and rutile TiO2 (110) layers together, in which a built‐in electric field induced from the electron transfer from TiO2 to CuCl (CuCl_BEF) is successfully formed . This built‐in electric field effectively triggers interfacial accumulation of NO3− ions around the electrocatalyst. The electric field also raises the energy of key reaction intermediate *NO to lower the energy barrier of the rate determining step. A NH3 product selectivity of 98.6 %, a low NO2− production of <0.6 %, and mass‐specific ammonia production rate of 64.4 h−1 is achieved, which are all the best among studies reported at 100 mg L−1 of nitrate concentration to date.
An electrocatalyst is created by stacking CuCl (111) and rutile TiO2 (110) layers together. A built‐in electric field induced from the electron transfer from TiO2 to CuCl (CuCl_BEF) is thus formed, which triggers interfacial accumulation of NO3− ions around the electrocatalyst. A NH3 product selectivity of 98.6 %, a low NO2− production of <0.6 %, and mass‐specific ammonia production rate of 64.4 h−1 is achieved.
Nitrate electrocatalytic reduction (NO3RR) for ammonia production is a promising strategy to close the N‐cycle from nitration contamination, as well as an alternative to the Haber–Bosch process with ...less energy consumption and carbon dioxide release. However, current long‐term stability of NO3RR catalysts is usually tens of hours, far from the requirements for industrialization. Here, symmetry‐broken Cusingle‐atom catalysts are designed, and the catalytic activity is retained after operation for more than 2000 h, while an average ammonia production rate of 27.84 mg h−1 cm−2 at an industrial level current density of 366 mA cm−2 is achieved, obtaining a good balance between catalytic activity and long‐term stability. Coordination symmetry breaking is achieved by embedding one Cu atom in graphene nanosheets with two N and two O atoms in the cis‐configuration, effectively lowering the coordination symmetry, rendering the active site more polar, and accumulating more NO3− near the electrocatalyst surface. Additionally, the cis‐coordination splits the Cu 3d orbitals, which generates an orbital‐symmetry‐matched π‐complex of the key intermediate *ONH and reduces the energy barrier, compared with the σ‐complex generated with other catalysts. These results reveal the critical role of coordination symmetry in single‐atom catalysts, prompting the design of more coordination‐symmetry‐broken electrocatalysts toward possible industrialization.
A coordination‐symmetry‐breaking Cusingle‐atom catalyst enables a good balance between catalytic activity and long‐term stability in nitrate electroreduction to ammonia. The catalytic activity is retained after operation for more than 2000 h, while an average ammonia production rate of 27.84 mg h−1 cm−2 at an industrial level current density of 366 mA cm−2 is achieved.
Interleukin-22 (IL-22) is an IL-10 family cytokine that was recently discovered to be released by T helper 17 (Th17) cells, Th22 cells,
etc
. Recently, there is emerging evidence that IL-22 is ...involved in the development and pathogenesis of psoriasis. For instance, IL-22 can inhibit keratinocyte terminal differentiation and can induce psoriasis-like epidermis alterations; serum IL-22 levels were correlated with the disease severity of psoriasis patients, and IL-22 mRNA was positively expressed in the psoriatic skin lesions, but negatively expressed in the normal controls. All these findings suggest that IL-22 may be implicated in psoriasis; therapeutics targeting IL-22 may have promise as a potential therapeutic target for treating psoriasis. In the present review, we summarize recent advances on the role of IL-22 in the pathogenesis and treatment of psoriasis.
Heavy consumption of fossil fuels has raised concerns over the climate change and energy security in the past decades. In this review, hydrogen economy, as a clean and sustainable energy system, is ...receiving great attention. The success of future hydrogen economy strongly depends on the storage of renewable energy in hydrogen and hydrogen-rich chemicals through electrolyzers and conversion back to electricity via fuel cells. Electrocatalysts are at the heart of these critical technologies and great efforts have been devoted to preparing highly efficient nanomaterials. High-entropy alloys (HEAs), with their unique structural characteristics and intrinsic properties, have evolved to be one of the most popular catalysts for energy-related applications, especially those associated with hydrogen economy. Herein, recent advances regarding HEAs-based hydrogen economy are comprehensively reviewed. Attention is paid to the discussion of emerged HEAs as a new class of materials in hydrogen energy cycle, carbon-based hydrogen energy cycle, and nitrogen-based hydrogen energy cycle, covering the sustainable electrochemical synthesis of hydrogen and hydrogen-rich fuels and their direct application in fuel cells. Based on this overview, the challenges and promising directions are proposed to guide the development of HEAs research, aiming to achieve significant progress for further accessing hydrogen economy.
Graphical Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are widely used to treat non-small cell lung cancer (NSCLC). However, acquired resistance ...is unavoidable, impairing the anti-tumor effects of EGFR-TKIs. It is reported that histone deacetylase (HDAC) inhibitors could enhance the anti-tumor effects of other antineoplastic agents and radiotherapy. However, whether the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) can overcome erlotinib-acquired resistance is not fully clear.
An erlotinib-resistant PC-9/ER cell line was established through cell maintenance in a series of erlotinib-containing cultures. NSCLC cells were co-cultured with SAHA, erlotinib, or their combination, and then the viability of cells was measured by the 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and apoptosis was determined by flow cytometry and western blotting. Finally, the expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was assessed by western blotting.
The half-maximal inhibitory concentration of parental PC-9 cells was significantly lower than the established erlotinib-acquired resistant PC-9/ER cell line. PC-9/ER cells demonstrated reduced expression of PTEN compared with PC-9 and H1975 cells, and the combination of SAHA and erlotinib significantly inhibited cell growth and increased apoptosis in both PC-9/ER and H1975 cells. Furthermore, treating PC-9/ER cells with SAHA or SAHA combined with erlotinib significantly upregulated the expression of PTEN mRNA and protein compared with erlotinib treatment alone.
PTEN deletion is closely related to acquired resistance to EGFR-TKIs, and treatment with the combination of SAHA and erlotinib showed a greater inhibitory effect on NSCLC cells than single-drug therapy. SAHA enhances the suppressive effects of erlotinib in lung cancer cells, increasing cellular apoptosis and PTEN expression. SAHA can be a potential adjuvant to erlotinib treatment, and thus, can improve the efficacy of NSCLC therapy.
Background: To investigate the prognostic significance of the cumulative score based on preoperative fibrinogen and pre-albumin (FP score) in patients with gastric cancer after radical gastrectomy. ...Methods: Baseline characteristics, preoperative fibrinogen and pre-albumin levels were retrospectively reviewed in patients who underwent radical gastrectomy. The optimal cut-off values for fibrinogen and pre-albumin were defined as 4.0 g/L and 230.0 mg/L, respectively. Patients with elevated fibrinogen (≥ 4.0 g/L) and decreased pre-albumin (< 230.0 mg/L) levels were allocated an FP score of 2, those with only one of these two abnormalities were assigned a score of 1, and those with neither of the two abnormalities were allocated a score of 0. The prognostic value was examined by univariate and multivariate regression analyses. Results: The preoperative FP score was significantly correlated with age, tumor size, fibrinogen level, pre-albumin level and white blood cell count. No significant differences based on sex, tumor location, degree of differentiation, depth of invasion, lymph node status, tumor-node-metastasis (TNM) stage or adjuvant chemotherapy were identified between the groups. In addition, univariate survival analysis revealed that a high preoperative FP score was significantly associated with unfavorable disease-free survival (DFS) hazard ratio (HR), 1.482; 95% confidence interval (CI), 1.222-1.796; P < 0.001 and overall survival (OS) (HR, 1.623; 95% CI, 1.315-2.002; P < 0.001). Moreover, after adjusting for other factors, a high preoperative FP score remained an independent predictor for impaired DFS (HR, 1.434; 95% CI, 1.177-1.747; P < 0.001) and OS (HR, 1.413; 95% CI, 1.136-1.758; P = 0.002) in multivariate Cox regression analysis. Conclusions: The preoperative FP score significantly predicts long-term survival for gastric cancer patients who have undergone radical gastrectomy.
The aim of this meta-analysis was to summarize the evidence on the serum/plasma leptin concentrations in breast cancer (BC) patients, as well as the associations between leptin
gene polymorphisms and ...susceptibility to BC.
Potentially relevant studies about serum/plasma leptin levels and leptin
gene polymorphism were selected using the electronic databases PubMed, EMBASE and The Cochrane Library (from January 1 1995 to Jun 30 2017, no language restrictions). The potential sources of heterogeneity were assessed by the
statistic and quantified using
; publication bias was qualitatively assessed by funnel plot and quantitatively assessed by Egger's linear regression test.
A total of 1141 articles were retrieved after database searches, and 27 studies with 9516 subjects (4542 BC patients/4974 controls) were finally included. The results indicated that BC patients had significantly higher leptin levels compared with healthy controls (SMD = 1.65, 95% CI: 1.21-2.09,
< 0.001), but there was no association between leptin
polymorphism and BC (OR = 1.05, 95% CI: 0.80-1.39,
0.722). Subgroup analyses demonstrated increased leptin levels in BC patients of different region, race, body mass index and waist circumference.
Our results revealed a significantly higher leptin level in BC patients than in healthy controls, but no association between leptin
polymorphism and BC susceptibility was found.
Despite promising developments of treatment, the overall outcome of gastric cancer (GC) remains poor. Current tumor markers are not ideal due to relatively low sensitivity and specificity. There is ...an urgent need for identifying more specific and more sensitive novel markers in the clinical management of GC. MicroRNAs (miRNAs) are non-coding RNA molecules. Recently, miRNA studies have quickly moved from basic molecular research of cancer to areas of clinical application. On the basis of recent data, the present review mainly summarizes the potential role of miRNAs as molecular biomarkers for disease susceptibility, diagnosis, prognosis and drug-response prediction in GC. This review also highlights the miRNA expression profiles in GC and their relation to cancer classification and subtype stratification. Although there are still many challenges in the research field of tumor-related miRNAs, the small molecules will definitely improve the clinical management of GC in the future.
Lumiracoxib is a highly selective cyclooxygenase-2 (COX-2) inhibitor with antiinflammatory, analgesic and antipyretic activities comparable with class specific drugs, but with much improved ...gastrointestinal safety. No studies have examined lumiracoxib for antitumorigenic activity on human nonsmall cell lung cancer cell lines in vitro or its possible molecular mechanisms.
The antiproliferative effect of lumiracoxib alone or combined with docetaxol on A549 and NCI-H460 lines was assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Drug-drug interactions were analyzed using the coefficient of drug interaction (CDI) to characterize the interactions as synergism, additivity or antagonism. Morphological changes were observed by acridine orange fluorescent staining. Extent of apoptosis was determined by flow cytometry.
Lumiracoxib (15 - 240 micromol/L) has an inhibitory effect on the proliferation of A549 and NCI-H460 cell lines in concentration- and time-dependent manners with the IC50 values of 2597 micromol/L and 833 micromol/L, respectively. The synergistic effect was prominent when lumiracoxib (15 - 240 micromol/L) was combined with docetaxol (0.2 - 2 micromol/L) (CDI < 1). Fluorescent staining showed that lumiracoxib could induce apoptosis in A549 and NCI-H460 cells. Lumiracoxib treatment also caused an increase of the sub-G1 fraction in each cell line and resulted in an increase of G0/G1-phase cells and a decrease of S-phase cells.
Lumiracoxib had antiproliferative effect on the human nonsmall cell lung cancer cell lines A549 and NCI-H460 and had a significant synergy with docetaxol, which may be related to apoptotic induction and cell cycle arrest.
PDF
